Mission Pharmacal Header

Mission Pharmacal Header

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Filters

×

FILTER:

filter

News Type

filter

Company

filter

Product Type

filter

Deal Size

filter

Upfront Payment

Active Filter(s):

Filters

Reset Filter

All Developments

Product Type

Companies

[{"company":"Molteni Farmaceutici","sponsor":"Titan Pharmaceuticals Inc","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Titan Pharma Completes Debt Settlement with Molteni and Horizon; Acquisition of JT-09","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Preclinical","country":"ITALY","productType":"Peptide","productStatus":"New Molecular Entity","date":"November 2020","url1":"","url2":"","graph1":"Peptide","graph2":"Molteni Farmaceutici"}]

Molteni Farmaceutici

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Titan Pharma Completes Debt Settlement with Molteni and Horizon; Acquisition of JT-09

Details:

As a result of the debt settlement with Molteni and Horizon, there are no liens remaining on any of Titan's assets. With the net proceeds from recent public the company is well positioned to progress preclinical development of its ProNeura-based pipeline and JT-09.

Lead Product(s): JT-09

Therapeutic Area: Dermatology Product Name: JT-09

Highest Development Status: Preclinical Product Type: Peptide

Partner/Sponsor/Collaborator: Titan Pharmaceuticals Inc

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Public Offering November 02, 2020

ASK
US

Upload
your Pipeline Activity

POST ENQUIRY